Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)

The three part, double‐blind, randomized, controlled reSURFACE 1 trial and extension study (NCT01722331) evaluated efficacy and safety of tildrakizumab in adults with moderate to severe plaque psoriasis. Patients with ≥50% improvement from baseline in Psoriasis Area and Severity Index (PASI 50) foll...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of dermatology 2021-06, Vol.48 (6), p.844-852
Hauptverfasser:	Imafuku, Shinichi, Nakagawa, Hidemi, Igarashi, Atsuyuki, Morita, Akimichi, Okubo, Yukari, Sano, Shigetoshi, Tada, Yayoi, Nemoto, Osamu, Rozzo, Stephen J., Kawamura, Masaki, Ohtsuki, Mamitaro
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events biologic therapy Clinical outcomes Hypersensitivity IL‐23p19 Immunotherapy Longitudinal studies Monoclonal antibodies Original Patient safety Psoriasis Psoriasis Area and Severity Index Safety tildrakizumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!